Current reimbursement models in general do not accommodate many of the unique factors common among gene and cell therapies. In this second article of a three-part series, CRA’s Walter Colasante, Pascale Diesel, and Lev Gerlovin discuss the challenges to demonstrating value and addressing affordability and discuss options for payment models.
The authors wish to acknowledge the contributions of Stephanie Donahue and Michael Krepps to this article.
Click here to read the article.
Ken Beers joins CRA's Life Sciences Practice as Vice President
CRA is proud to welcome Kenneth J. Beers as a vice president in the Life Sciences Practice. Mr. Beers supports biopharmaceutical clients across a range of...